Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study - Paz-Ares, L; Solsona, E; Esteban, E (J Clin Oncol, 2010)
(Suppl.)